Management of Comment Adverse Effects Associated with mCRPC Therapies

Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.

EP: 1.Expert Perspective on the Expanding Treatment Landscape in mCRPC

EP: 2.The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC

Now Viewing

EP: 3.Management of Comment Adverse Effects Associated with mCRPC Therapies

EP: 4.Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC

EP: 5.Overview of Abiraterone and the Differences Between Formulations

EP: 6.Combining Abiraterone with Steroids

EP: 7.The Importance of Serum Testosterone Levels With the Use of Androgen Receptor-Targeting Therapies

EP: 8.Clinical Attributes of Patients Who Would Benefit From Micronized Abiraterone

EP: 9.Dosing and Administration Considerations for Abiraterone Formulations

EP: 10.Access Challenges Regarding the Use of Abiraterone in Patients With mCRPC

EP: 11.Future Directions in mCRPC

How do you manage common side effects associated with mCRPC treatments, including androgen receptor-targeted therapies?

Related Videos

Related Content

Advertisement

May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke

Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.

May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke

Use of focal therapy was shown to prolong the duration of active surveillance.

May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD

Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

Related Content

Advertisement

May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke

Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.

May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS

Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.

May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke

Use of focal therapy was shown to prolong the duration of active surveillance.

May 2nd 2025

Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

Amy M. Pearlman, MD

Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.

May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”